IDX 184 and IDX 719 safety data presented by Indenix.
Idenix has announced the presentation of safety and antiviral activity results for the Company's clinical-stage Hepatitis C virus (HCV) drug candidates � IDX 719, a next-generation pan-genotypic NS5A inhibitor, and IDX 184, a nucleotide polymerase inhibitor. Idenix presented updated clinical findings from a three-day proof-of-concept study, which demonstrated that IDX 719 was well-tolerated at daily doses up to 100 mg and showed potent antiviral activity across HCV genotypes 1-4, with mean maximal viral load reductions up to approximately 4.0 log10 IU/mL.
The Company also presented updated cardiovascular safety and antiviral activity data from the phase IIb study of IDX 184 in combination with pegylated interferon and ribavirin (PegIFN/RBV). The IDX 719 and IDX 184 clinical data are being reported in poster presentations during the 63rd Annual Meeting for the American Association for the Study of Liver Diseases (AASLD) in Boston.
The partial clinical hold by the FDA on IDX 184 has been lifted and Idenix can continue with a Phase IIb trial evaluating the product.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.